Article Figures & Data
Figures
- Figure 1.
Seven patients immunoprecipitated proteins of apparent molecular weight 142 kDa from 35S methionine-labeled K562 whole-cell extract, separated on an 8% SDS polyacrylamide 20-cm gel (data not shown). Immunoprecipitation was repeated for these 7 patients and the proteins electrophoretically resolved on a 5% SDS polyacrylamide minigel, enhanced with sodium salicylate and visualized by autoradiography (shown here). Lanes 1–6 represent patients included as “MJ” in Table 2; Lane 7, a patient included as “p155/140” in Table 2. Also shown is a 14C molecular weight marker (Mr).
Tables
- Table 1.
Demographic features of 64 patients with childhood idiopathic inflammatory myopathies. Of the 17 patients with myositis overlap syndromes, 3 had mixed connective tissue disease, 3 had systemic lupus erythematosus, and the remainder had myositis in overlap with other connective tissue diseases.
Feature Total, n = 64 JDM, n = 40 JPM, n = 7 Myositis Overlap Syndromes, n = 17 Sex F/M 48/16 30/10 5/2 13/4 Mean age at onset, yrs 8.3 8.7 9.8 10.8 Mean disease duration, yrs 4.5 4 3.5 4.8 Mean followup, yrs 3 3 3 3.8 -
JDM: Juvenile dermatomyositis; JPM: Juvenile polymyositis.
-
- Table 2.
Clinical features in patients with single myositis-specific autoantibody (MSA) or myositis-associated autoantibody (MAA). Four patients not included in the table had 2 autoantibodies: 2 with PM-Scl/Ku, 1 with PM-Scl/MJ, 1 with MJ/Mi-2. Four patients also possessed the anti-Sm autoantibody, which is not an MSA or MAA.
Clinical Manifestation Mi-2 (n = 4) PM-Scl (n = 2) U1RNP (n = 7) Ku (n=l) MJ (n = 16) p155/140 (n = 14) Sex F/M 3/1 1/1 5/2 1/0 12/4 11/3 Diagnosis JPM — — — — 2 — JDM 4 1 3 — 13 11 JOS — 1 4 1 1 3 Dysphagia 2 1 — — 5 3 Muscular Proximal weakness 4 2 7 1 14 14 Contractures — 1 1 — 7 7 Atrophy 4 1 — — 7 2 DM cutaneous signs 4 — 1 — 14 11 Cutaneous vasculitis — 1 1 — 6 8 Calcinosis 1 — — — 5 5 Interstitial lung disease — 1 2 — 4 1 Arthritis 1 1 3 — 6 9 Raynaud phenomenon — 2 3 — 1 4 -
JOS: juvenile overlap syndrome; JPM: juvenile polymyositis; JDM: juvenile dermatomyositis.
-
- Table 3.
Correlation of disease course with autoantibody in a subset of juvenile myositis patients with 2+ years of followup.
Feature Mi-2, n = 4 PM-Scl, n = 2 U1RNP, n = 6 Ku, n = 1 MJ, n = 10 p155/140, n = 13 Course Monocyclic 3 1 4 — 5 10 Polycyclic 1 1 2 1 4 2 Chronic-continuous — — — — 1 1 Functional status I–II 4 2 6 1 7 13 III–IV — — — — 3 — Disease activity Active 1 1 1 1 4 8 Inactive 3 1 5 — 6 5
In this issue
